​

Poseida Therapeutics (PSTX) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Poseida Therapeutics Revenue Highlights

Latest Revenue (Y)

$64.70M

Latest Revenue (Q)

$71.75M

Main Segment (Y)

Collaboration Revenue

Poseida Therapeutics Revenue by Period

Poseida Therapeutics Revenue by Year

DateRevenueChange
2023-12-31$64.70M-50.37%
2022-12-31$130.36M417217.08%
2021-12-31$31.24K100.00%
2020-12-31-100.00%
2019-12-31-100.00%
2018-12-31--100.00%
2017-12-31$2.98M-

Poseida Therapeutics generated $64.70M in revenue during NA 2023, up -50.37% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Poseida Therapeutics Revenue by Quarter

DateRevenueChange
2024-09-30$71.75M176.24%
2024-06-30$25.97M-7.71%
2024-03-31$28.14M12.59%
2023-12-31$25.00M167.27%
2023-09-30$9.35M-53.27%
2023-06-30$20.01M93.49%
2023-03-31$10.34M4.26%
2022-12-31$9.92M-91.47%
2022-09-30$116.31M4207.63%
2022-06-30$2.70M88.15%
2022-03-31$1.44M4493.76%
2021-12-31$31.24K100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31-100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31-100.00%
2018-12-31-100.00%
2017-12-31--

Poseida Therapeutics generated $71.75M in revenue during Q3 2024, up 176.24% compared to the previous quarter, and up 358.51% compared to the same period a year ago.

Poseida Therapeutics Revenue Breakdown

Poseida Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21
Collaboration Revenue$64.70M$130.49M$31.24M

Poseida Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Collaboration Revenue (100.00%).

Quarterly Revenue by Product

Product/ServiceSep 24Jun 24Mar 24Dec 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22
Collaboration Revenue$71.75M$25.97M$28.14M$34.35M$20.01M$10.34M$10.05M$116.31M$2.70M$1.44M

Poseida Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Collaboration Revenue (100.00%).

Poseida Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
PSTXPoseida Therapeutics$64.70M$71.75M
RVMDRevolution Medicines$11.58M-
STOKStoke Therapeutics$8.78M$4.89M
CYTKCytokinetics$7.53M$463.00K
MOLNMolecular Partners$7.04M$2.74M
GBIOGeneration Bio$5.90M$4.09M
CUECue Biopharma$5.49M$3.34M
IPSCCentury Therapeutics$2.23M$791.00K
PLRXPliant Therapeutics$1.58M-
ANTXAN2 Therapeutics--
PHVSPharvaris--
RVPHReviva Pharmaceuticals--
DYNDyne Therapeutics--
INABIN8bio--
PASGPassage Bio--
MLYSMineralys Therapeutics--
LTRNLantern Pharma--
PEPGPepGen--

PSTX Revenue FAQ

What is Poseida Therapeutics’s yearly revenue?

Poseida Therapeutics's yearly revenue for 2023 was $64.7M, representing a decrease of -50.37% compared to 2022. The company's yearly revenue for 2022 was $130.36M, representing an increase of 417217.08% compared to 2021. PSTX's yearly revenue for 2021 was $31.24K, representing an increase of 100.00% compared to 2020.

What is Poseida Therapeutics’s quarterly revenue?

Poseida Therapeutics's quarterly revenue for Q3 2024 was $71.75M, a 176.24% increase from the previous quarter (Q2 2024), and a 667.19% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $25.97M, a -7.71% decrease from the previous quarter (Q1 2024), and a 29.78% increase year-over-year (Q2 2023). PSTX's quarterly revenue for Q1 2024 was $28.14M, a 12.59% increase from the previous quarter (Q4 2023), and a 172.09% increase year-over-year (Q1 2023).

What is Poseida Therapeutics’s revenue growth rate?

Poseida Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 207029.14%, and for the last 5 years (2019-2023) was 0%.

What are Poseida Therapeutics’s revenue streams?

Poseida Therapeutics's revenue streams in c 23 are Collaboration Revenue

What is Poseida Therapeutics’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Poseida Therapeutics was Collaboration Revenue. This segment made a revenue of $64.7M, representing 100.00% of the company's total revenue.